Immunai is a biotech company that applies artificial intelligence and machine learning to decode the human immune system, with the aim of accelerating drug discovery. Its work sits at the intersection of computational biology, single-cell multiomics, and immunology. The company was founded by researchers from MIT and Harvard, and its team comprises immunologists, engineers, drug developers, computer scientists, and entrepreneurs.
The company's core asset is AMICA, described as the world's largest immune-focused single-cell database, containing harmonized data from thousands of samples. This database underpins an end-to-end platform designed to support pharmaceutical and research partners across the drug development process, from target discovery and preclinical evaluation to clinical trial optimization.
Immunai's platform is applied across several therapeutic areas, including immuno-oncology and autoimmune diseases. The company's stated goal is to bring breakthrough medicines to patients faster by enabling better-informed decisions at each stage of development.
